Q-omics provides the consensus-scored APOBEC3H profile across patient tissues and cancer cell-line models. APOBEC3H expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, APOBEC3H is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, APOBEC3H RNA expression shows 14,655 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight BLCA, KIRC, and LUAD as cancer lineages where APOBEC3H shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for APOBEC3H — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes APOBEC3H survival associations across molecular data types. APOBEC3H RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible APOBEC3H RNA expression–survival associations across cancer types. High APOBEC3H expression shows unfavorable associations in LGG, KIRC and SCLC, but favorable associations in BLCA, CESC and SKCM. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for APOBEC3H RNA expression.
This table summarizes APOBEC3H tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for APOBEC3H. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. APOBEC3H shows higher tumor expression in KIRC, THCA, KIRP, HNSC, STAD and LIHC. The KIRC box plot shows higher APOBEC3H RNA expression in tumor versus normal tissue (log2 FC = +1.604, t-test p < 0.001).
This table shows molecular features associated with APOBEC3H in patient tissues and cancer cell lines. In patient samples, APOBEC3H shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, APOBEC3H RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
